Macrophage Migration Inhibitory Factor in Cancer

Yasasever, Vildan; Çamlıca, Hakan; Duranyıldız, Derya; Oğuz, Hilal; Taş, Faruk; Dalay, Nejat

doi:10.1080/07357900701560695

Cited by 29 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mice were immunized with an emulsion containing 50 mg purified MIF [19][20][21][22][23][24][25][26][27] / HLA-A2 complexes and Quil-A adjuvant (Sigma-Aldrich, St. Louis, MO) to produce TCR mimic (TCRm) as previously described (29,30).…”

Section: Immunizationmentioning

confidence: 99%

“…T2 cells (1 3 10 6 ) were pulsed in RPMI 1640 and 1% FCS overnight with 10-fold dilutions of MIF [19][20][21][22][23][24][25][26][27] or 10 mM irrelevant peptide. Pulsed T2, total WBCs, and breast cancer cell lines were stained with 1 mg/ml RL21A Ab, BB7.2, or isotype controls, followed by PE-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories).…”

Section: Flow Cytometrymentioning

confidence: 99%

“…The resulting data demonstrate that the MIF 19-27 /HLA-A2 complex distinguishes invasive breast cancer tissue from normal breast tissue. Additionally, initial testing of the MIF [19][20][21][22][23][24][25][26][27] /HLA-A2 complex as an in vivo and in vitro target for the RL21A Ab provides encouraging data that support further development of immunotherapeutics directed toward MIF/HLA complexes.…”

mentioning

confidence: 99%

“…Several groups have explored MIF as a cancer diagnostic and therapeutic tool, and MIF secretion was initially used as a breast cancer prognostic in the leukocyte migration test (21). Serum MIF levels have likewise been proposed as a biomarker for prostate (22), colorectal (23), and breast cancer (24). Additionally, MIF has drawn a great deal of attention in cancer and autoimmune disease as a potential therapeutic target for neutralizing Abs, small interfering RNA, and small molecule inhibitors (25)(26)(27).…”

mentioning

confidence: 99%

See 3 more Smart Citations

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

Hawkins

Verma

Lightfoot

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

This report describes a novel HLA/peptide complex with potential prognostic and therapeutic roles for invasive breast cancer. Macrophage migration inhibitory factor (MIF) mediates inflammation and immunity, and MIF overexpression is observed in breast cancer. We hypothesized that the HLA class I of cancerous breast epithelial cells would present MIF-derived peptides. Consistent with this hypothesis, the peptide FLSELTQQL (MIF19–27) was eluted from the HLA-A*0201 (HLA-A2) of breast cancer cell lines. We posited that if this MIF19–27/HLA-A2 complex was exclusively found in invasive breast cancer, it could be a useful prognostic indicator. To assess the presentation of MIF peptides by the HLA of various cells and tissues, mice were immunized with the MIF19–27/HLA-A2 complex. The resulting mAb (RL21A) stained invasive ductal carcinoma (IDC) but not ductal carcinoma in situ, fibroadenoma, or normal breast tissues. RL21A did not stain WBCs (total WBCs) or normal tissues from deceased HLA-A2 donors, substantiating the tumor-specific nature of this MIF/HLA complex. As this MIF/HLA complex appeared specific to the surface of IDC, RL21A was tested as an immunotherapeutic for breast cancer in vitro and in vivo. In vitro, RL21A killed the MDA-MB-231 cell line via complement and induction of apoptosis. In an in vivo orthotopic mouse model, administration of RL21A reduced MDA-MB-231 and BT-20 tumor burden by 5-fold and by >2-fold, respectively. In summary, HLA-presented MIF peptides show promise as prognostic cell surface indicators for IDC and as targets for immunotherapeutic intervention.

show abstract

Section: Immunizationmentioning

confidence: 99%

Section: Flow Cytometrymentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

Hawkins

Verma

Lightfoot

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Molecules associated with cancer have been extensively investigated and used in clinical practice for more than 30 years. These serum "tumor markers" play an important role in the management of many malignancies (Yasasever et al, 2007). Generally, tumor markers have low specificity and sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer

Soydinc

Duranyıldız²,

Güney³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Malignant tumors have a capacity to degrade the extracellular matrix by controlled proteolysis. One system involved in these processes is the urokinase-type plasminogen activator (uPA) system. uPAR levels are elevated in tumors from several types of cancer. Our study was planned to investigate serum and urine levels of uPAR in breast cancer patients (n=180) and healthy controls (n=60) by ELISA. Serum (p<0.001) and urine (p<0.001) uPAR values in the patients were both significantly elevated. High serum and urine levels of uPAR can be used as diagnostic tools in lymph node positive patients.

show abstract

Serum macrophage migration‐inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer

Xia

Yang

Chu

et al. 2009

Cancer

View full text Add to dashboard Cite

Ethylene‐propylene‐diene terpolymers (EPDM) are generally amorphous and, therefore, do not crystallize from solution. Consequently, fractionation techniques based on crystallization, such as crystallization analysis fractionation or temperature rising elution fractionation, cannot be used to analyze their chemical composition distribution. Moreover, no suitable chromatographic system was known, which would enable to separate them according to their chemical composition. In this study, two different sorbent/solvent systems are tested with regard to the capability to separate EPDM‐terpolymers and ethylene‐propylene (EP)‐copolymers according to chemical composition. While porous graphite/1‐decanol system is selective towards ethylene and ethylidene‐2‐norbornene, carbon coated zirconia/2‐ethyl‐1‐hexanol is preferentially selective towards ethylene. Consequently, the earlier system enables to separate both EP copolymers and EPDM according to the chemical composition and the latter mainly according to the ethylene content. The results prove that the chromatographic separation in both sorbent/solvent systems is not influenced by molar mass of a sample or by its long chain branching. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

Macrophage Migration Inhibitory Factor in Cancer

Cited by 29 publications

References 32 publications

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer

Serum macrophage migration‐inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer

Contact Info

Product

Resources

About